NovaBridge's gastric cancer antibody, givastomig, has received FDA Fast Track designation. The company is also advancing trials for an eye drug, with recent developments including the addition of new leadership and board members. NovaBridge reportedly has sufficient cash to continue operations through 2028 as these trials progress.